U. S. Food and Drug Administration has approved the blood-thinning drug Plavix to be available in generic versions in pharmacies, a report has revealed.
The application for the drug’s, with generic name clopidogrel, generic application was given by Pittsburgh-based Mylan Pharmaceuticals at first. According to the same, it will be the only one to sell the generic version in the market.
The drug is meant for those who either have a heart disease or have a family history of strokes and heart disease and want to avoid clotting problems and further risks.
It has been found that the drug was previously marketed by Sanofi-Aventis in collaboration with Bristol-Myers Squibb. A total of $6.7 billion for the last year has been made by its US sales, as per the findings.
The FDA has set different levels of dosage of the drug to be supplied by different pharmaceutical companies. It is being said that Dr. Reddy’s Laboratories, Gate Pharmaceuticals and Mylan along with Teva Pharmaceuticals would sell 300-milligram tablets of clopidogrel. And Aurobindo Pharma, Mylan, Roxane Laboratories, Teva and some others would sell the 75-milligram dosage.
- Finally a $7 Billion Settlement for Citigroup
- Discussions In Progress for Merger of Tobacco Businesses: Reynolds to Acquire Lorillard
- Amazon Seeks Permission to Fly Drones for Delivery of Packages from FAA
- Wells Fargo Reports a Profit
- Abbott hits JV deal with Fonterra to operate diary farms in China